BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,951,407 | -44.8% | 190,266 | -33.8% | 0.00% | -25.0% |
| Q2 2023 | $23,449,033 | +55.8% | 287,260 | +41.6% | 0.00% | +33.3% |
| Q1 2023 | $15,051,519 | +35.8% | 202,878 | +51.7% | 0.00% | +50.0% |
| Q4 2022 | $11,087,521 | +6.2% | 133,778 | +263.8% | 0.00% | -33.3% |
| Q3 2022 | $10,443,000 | +75.6% | 36,769 | +114.4% | 0.00% | +50.0% |
| Q2 2022 | $5,946,000 | -51.4% | 17,153 | -39.3% | 0.00% | 0.0% |
| Q1 2022 | $12,243,000 | -73.9% | 28,272 | -68.8% | 0.00% | 0.0% |
| Q4 2021 | $46,860,000 | +178.7% | 90,580 | +161.0% | 0.00% | 0.0% |
| Q3 2021 | $16,815,000 | -81.5% | 34,703 | -82.8% | 0.00% | -83.3% |
| Q2 2021 | $90,693,000 | +699.7% | 201,422 | +578.3% | 0.01% | +500.0% |
| Q1 2021 | $11,341,000 | +40.0% | 29,694 | +16.4% | 0.00% | – |
| Q4 2020 | $8,100,000 | -33.7% | 25,506 | -48.3% | 0.00% | -100.0% |
| Q3 2020 | $12,222,000 | -26.8% | 49,336 | -22.0% | 0.00% | -50.0% |
| Q2 2020 | $16,693,000 | +58.0% | 63,213 | +13.5% | 0.00% | +33.3% |
| Q1 2020 | $10,564,000 | +203.6% | 55,711 | +251.5% | 0.00% | – |
| Q4 2019 | $3,480,000 | +34.7% | 15,851 | +20.0% | 0.00% | – |
| Q3 2019 | $2,584,000 | -79.9% | 13,206 | -78.6% | 0.00% | -100.0% |
| Q2 2019 | $12,867,000 | +561.2% | 61,718 | +529.8% | 0.00% | 0.0% |
| Q1 2019 | $1,946,000 | +236.7% | 9,800 | +145.0% | 0.00% | – |
| Q4 2018 | $578,000 | -61.7% | 4,000 | -45.9% | 0.00% | – |
| Q3 2018 | $1,510,000 | -15.0% | 7,400 | -38.3% | 0.00% | – |
| Q2 2018 | $1,776,000 | +2.2% | 12,000 | +4.3% | 0.00% | – |
| Q1 2018 | $1,737,000 | +229.0% | 11,500 | +182.1% | 0.00% | – |
| Q4 2017 | $528,000 | -43.3% | 4,076 | -47.1% | 0.00% | – |
| Q3 2017 | $931,000 | -51.7% | 7,700 | -53.0% | 0.00% | -100.0% |
| Q2 2017 | $1,927,000 | +49.3% | 16,400 | +29.1% | 0.00% | – |
| Q1 2017 | $1,291,000 | +315.1% | 12,700 | +319.4% | 0.00% | – |
| Q4 2016 | $311,000 | +37.6% | 3,028 | +51.4% | 0.00% | – |
| Q2 2016 | $226,000 | -82.8% | 2,000 | -86.3% | 0.00% | – |
| Q4 2015 | $1,316,000 | -60.8% | 14,621 | -59.8% | 0.00% | -100.0% |
| Q3 2015 | $3,360,000 | +55.3% | 36,338 | +65.4% | 0.00% | 0.0% |
| Q2 2015 | $2,164,000 | +58.7% | 21,975 | +61.6% | 0.00% | 0.0% |
| Q1 2015 | $1,364,000 | – | 13,601 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |